Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
Endocr Pathol. 2019 Dec;30(4):318-328. doi: 10.1007/s12022-019-09587-0.
Somatic GNAS and USP8 mutations have been implicated in sporadic somatotrophinomas and corticotrophinomas, respectively. However, no genes are known to be recurrently mutated in sporadic prolactinomas. The prevalence of copy number variants (CNV), which is emerging as a mechanism of tumorigenesis in sporadic pituitary adenomas in general, is also unclear in prolactinomas. To characterize the genetic events underpinning sporadic prolactinomas, we performed whole exome sequencing of paired tumor and germline DNA from 12 prolactinoma patients. We observed recurrent large-scale CNV, most commonly in the form of copy number gains. We also identified sequence variants of interest in 15 genes. This included the DRD2, PRL, TMEM67, and MLH3 genes with plausible links to prolactinoma formation. Of the 15 genes of interest, CNV was seen at the gene locus in the corresponding tumor in 10 cases, and pituitary expression of eight genes was in the top 10% of tissues. However, none of our shortlisted somatic variants appeared to be classical driver mutations as no variant was found in more than one tumor. Future directions of research include mechanistic studies to investigate how CNV may contribute to prolactinoma formation, larger studies of relevant prolactinoma subsets according to clinical characteristics, and additional genetic investigations for aberrations not captured by whole exome sequencing.
体细胞 GNAS 和 USP8 突变分别与散发性生长激素细胞瘤和促肾上腺皮质激素细胞瘤有关。然而,目前还没有已知的基因在散发性催乳素瘤中经常发生突变。拷贝数变异(CNV)的普遍性,作为一般散发性垂体腺瘤发生肿瘤的机制之一,在催乳素瘤中也不清楚。为了描述散发性催乳素瘤的遗传事件,我们对 12 例催乳素瘤患者的肿瘤和生殖系 DNA 进行了全外显子组测序。我们观察到反复出现的大规模 CNV,最常见的形式是拷贝数增加。我们还在 15 个基因中鉴定了感兴趣的序列变异。这包括 DRD2、PRL、TMEM67 和 MLH3 基因,它们与催乳素瘤的形成有明显的联系。在 15 个感兴趣的基因中,有 10 例肿瘤中相应基因座存在 CNV,其中 8 个基因的垂体表达位于组织的前 10%。然而,我们没有发现任何一个被列入候选的体细胞变异似乎是经典的驱动突变,因为没有一个变异在超过一个肿瘤中被发现。未来的研究方向包括对 CNV 如何促进催乳素瘤形成的机制进行研究,根据临床特征对相关催乳素瘤亚组进行更大规模的研究,以及对全外显子组测序未捕获的异常进行额外的遗传研究。